Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Maitreya Medicare's Debt-to-EBITDA or its related term are showing as below:
NSE:MAITREYA's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.19 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Maitreya Medicare Debt-to-EBITDA Related Terms
Maitreya Medicare Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Maitreya Medicare's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maitreya Medicare Debt-to-EBITDA Chart
Maitreya Medicare Annual Data
Trend
Mar21
Mar22
Mar23
Debt-to-EBITDA
1.23
2.13
0.75
Maitreya Medicare Semi-Annual Data
Mar21
Mar22
Mar23
Sep23
Debt-to-EBITDA
N/A
N/A
N/A
0.57
NSE:MAITREYA vs HCA, DVA, THC: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Maitreya Medicare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maitreya Medicare Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Maitreya Medicare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maitreya Medicare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.
Maitreya Medicare (NSE:MAITREYA) has a Debt-to-EBITDA of 0.57 as of Sep. 2023. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maitreya Medicare.
Is Maitreya Medicare's Debt-to-EBITDA too high?
Maitreya Medicare's current Debt-to-EBITDA is 0.57. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Maitreya Medicare's value of 0.57 is 74% below this industry median. Overall, Maitreya Medicare has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Maitreya Medicare's Debt-to-EBITDA compare to HCA and DVA?
Maitreya Medicare's Debt-to-EBITDA of 0.57 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.19. Maitreya Medicare's value of 0.57 is 74% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maitreya Medicare's current Debt-to-EBITDA of 0.57 is 74% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maitreya Medicare. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maitreya Medicare's current Debt-to-EBITDA is 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maitreya Medicare stock overvalued right now?
Maitreya Medicare (NSE:MAITREYA) has a current Debt-to-EBITDA of 0.57. The current Debt-to-EBITDA is 0.57 and 74% below the Healthcare Providers & Services industry median of 2.19. Maitreya Medicare's overall GF Score™ is 18/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Maitreya Medicare (NSE:MAITREYA), the current Debt-to-EBITDA is 0.57 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maitreya Medicare Ltd is Multi Superspeciality hospital. It is a 125 bedded hospital that provides multi-disciplinary integrated healthcare services, with a focus on primary secondary & tertiary care, and also offers a comprehensive range of healthcare services across over 18 specialties and super specialties, including Cardiology, Urology, Oncology, Laparoscopic Surgery, Neurology, Neurosurgery, Spine Surgery, Nephrology including Dialysis, Gastroenterology, Gastrointestinal surgery, Cardiothoracic Surgery, Oncosurgery, Orthopedic Surgery including joint replacements and Arthroscopic surgeries, Gynecology & High-Risk Obstetrics, Hepatocellular Billary Surgery, Critical Care Medicine etc.
18GF Score
Get the complete analysis for NSE:MAITREYA
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAITREYA has been successfully added to your 
